Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Nanoveu (NVU) is set to incorporate its antiviral nanotechnology in its smartphone and tablet screen protectors and cases
  • The copper-based particles that are present in the screen protectors react with atmospheric oxygen to kill micro organisms and viruses
  • Initial testing has demonstrated effectiveness against influenza A and E. coli
  • Laboratories in the U.S. and Singapore will continue testing against the human coronavirus OC43, which is the same genus as COVID-19
  • Procurement is underway for the first production run of smartphone screens, with product availability expected later this year
  • Nanoveu has skyrocketed 100 per cent and shares are trading for six cents each

Nanoveu (NVU) is set to incorporate its proprietary antiviral nanotechnology in its smartphone and tablet screen protectors and cases.

The company manufactures a range of products designed to enhance the use of handheld technologies, including its EyeFly3D and EyeFyx products.

Nanoveu’s latest offering was developed in-house by its research team using active copper-based nanoparticles dispersed throughout a translucent surface. 

The copper particles react with atmospheric oxygen to produce a redox reaction, which in turn activates oxygen molecules that are effective in killing micro organisms and smaller organic structures such as viruses.

Based on initial testing with a select group of planned products, the technology has a proven effectiveness against a range of viruses and bacteria, including influenza A and E. coli.

Nanoveu has now engaged independent laboratories in the U.S. and Singapore to conduct further testing, focussing on the human coronavirus OC43, which is the same genus as SARS-CoV-2.

The company is already making procurements for an initial production run of screens and cases, although this is dependent on regulatory approval.

As such, Nanoveu has appointed several consultants to assist in compliance with the Australian Therapeutic Goods Administration (TGA). The company plans to submit an application for approval as a Class I Medical Device.

Alfred Chong, Executive Chairman and CEO of Nanoveu, said that the advent of COVID-19 presented an opportunity for the company to advance its existing antimicrobial technologies.

“Mobile phones are both ubiquitous and rely upon touch to operate, making them prime candidates for the spread of disease,” Alfred said.

“Therefore, we anticipate that there will be strong interest in a technology which can protect phone users from viruses and bacteria in a way which is non-invasive and unobtrusive,” he added.

Pending further studies and regulatory approval, Nanoveu expects that its products will have a rapid commercialisation schedule, with first pre-orders planned for the second quarter of the 2020 calendar year.

Nanoveu has skyrocketed 100 per cent and shares are trading for six cents each at 10:30 am AEST.

NVU by the numbers
More From The Market Herald
The Market Herald Video

" Ava Risk Group (ASX:AVA) secures two more US contracts for $1.2m

Ava Risk Group (ASX:AVA) has secured a further two contracts for the supply and installation of…
The Market Herald Video

" Emyria (ASX:EMD) launches phase 3 EMD-RX5 trial

Emyria (ASX:EMD) has launched its phase three clinical trial of its ultra-pure CBD candidate.
The Market Herald Video

" Prescient Therapeutics (ASX:PTX) locks in OmniCAR cell manufacturing contract for clinical trials

Prescient Therapeutics (ASX:PTX) has signed a manufacturing services agreement with Q-Gen Cell Therapeutics to produce its…
The Market Herald Video

" Opthea (ASX:OPT) secures up to US$260m in funding for OPT-302 trials

Opthea (ASX:OPT) secures up to US$170 million in financing and a US$90 million placement to advance…